{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:53:58Z","timestamp":1793904838921,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.medj.2024.05.008","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T12:27:47Z","timestamp":1718195267000},"page":"1137-1149.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial"],"prefix":"10.1016","volume":"5","author":[{"given":"Mingming","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shegan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoxing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6312-9299","authenticated-orcid":false,"given":"Huiyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.05.008_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.medj.2024.05.008_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","article-title":"Oesophageal carcinoma","volume":"381","author":"Pennathur","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.05.008_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5732\/cjc.011.10390","article-title":"Epidemiologic differences in esophageal cancer between Asian and Western populations","volume":"31","author":"Zhang","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.medj.2024.05.008_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1998.524","article-title":"Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer","volume":"78","author":"Petrasch","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2024.05.008_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/COC.0b013e3181131ca9","article-title":"A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus","volume":"31","author":"Zhang","year":"2008","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000495700","article-title":"Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma","volume":"42","author":"Sun","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.medj.2024.05.008_bib7","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1002\/mef2.56","article-title":"Chemoimmunotherapy for esophageal squamous cell carcinoma\u2014Summary and discussion of recent clinical trials","volume":"2","author":"Zhang","year":"2023","journal-title":"MedComm\u00a0\u2013 Future Med."},{"key":"10.1016\/j.medj.2024.05.008_bib8","doi-asserted-by":"crossref","first-page":"3836855","DOI":"10.1155\/2023\/3836855","article-title":"Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis","volume":"2023","author":"Ma","year":"2023","journal-title":"J.\u00a0Clin. Pharm. Ther."},{"key":"10.1016\/j.medj.2024.05.008_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s44178-023-00028-x","article-title":"Chemo-immunotherapy in advanced esophageal squamous cell carcinoma: present and future","volume":"2","author":"Wang","year":"2023","journal-title":"Holist. Integ. Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.05.008_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.05.008_bib12","doi-asserted-by":"crossref","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2024.05.008_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2024.05.008_bib14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib16","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.medj.2024.05.008_bib19","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.05.008_bib20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2024.05.008_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ags3.12294","article-title":"Prognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta-analysis","volume":"4","author":"Ishibashi","year":"2020","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.medj.2024.05.008_bib22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3389\/fonc.2020.00797","article-title":"Prognostic Value of Pre-Treatment Prognostic Nutritional Index in Esophageal Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"Hao","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib23","doi-asserted-by":"crossref","first-page":"103427","DOI":"10.1016\/j.critrevonc.2021.103427","article-title":"Prognostic value of platelet-related measures for overall survival in esophageal squamous cell carcinoma: A systematic review and meta-analysis","volume":"164","author":"Ishibashi","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.medj.2024.05.008_bib24","article-title":"Esophageal and esophagogastric junction cancers","year":"2020","journal-title":"NCCN Clinical Practice Guidelines in Oncology"},{"key":"10.1016\/j.medj.2024.05.008_bib25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2147\/DDDT.S105441","article-title":"Comparison of cisplatinum\/paclitaxel with cisplatinum\/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients","volume":"10","author":"Hu","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.medj.2024.05.008_bib26","first-page":"2345","article-title":"Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer","volume":"6","author":"Liu","year":"2016","journal-title":"J.\u00a0Cancer Res."},{"key":"10.1016\/j.medj.2024.05.008_bib27","first-page":"316","article-title":"A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus","volume":"6","author":"Ilson","year":"2000","journal-title":"Cancer J."},{"key":"10.1016\/j.medj.2024.05.008_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"7","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2024.05.008_bib30","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.05.008_bib31","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib32","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1200\/JCO.2011.38.8751","article-title":"Influence of sex on the survival of patients with esophageal cancer","volume":"30","author":"Bohanes","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib33","doi-asserted-by":"crossref","first-page":"836914","DOI":"10.3389\/fpubh.2022.836914","article-title":"Age-Related Sex Disparities in Esophageal Cancer Survival: A Population-Based Study in the United States","volume":"10","author":"Xiang","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.medj.2024.05.008_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2024.05.008_bib35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch. Pathol. Lab Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:31:22Z","timestamp":1759865482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024002125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666634024002125"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.05.008","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}